Statins for Venous Event Reduction in Patients With Venous Thromboembolism
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2700 participants.
Also called NCT04319627
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,700 participants
- Sponsor
- Registry
-
NCT04319627
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada, France, Ireland, Italy, Norway, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT04319627. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-10 (actual); primary completion 2028-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Statins for Venous Event Reduction in Patients With Venous Thromboembolism
- Acronym
- SAVER
- Condition
- Venous Thromboembolism
- Condition
- Blood Clot
- Condition
- Post Thrombotic Syndrome
- Intervention (Drug)
- Rosuvastatin Calcium
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Ottawa Hospital Research Institute
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Eastern Norway Health Authorities RHF
- Collaborator
- Southern health region, Norway
- Collaborator
- Programme hospitalier de recherche clinique, France
- Collaborator
- British Heart Foundation
Record details
- Record id
cardio:ct-nct04319627- Content hash
7373972b18130d70815aa8dc699734f7756c8cb3d1503e78e2c58cc82f37ca6e